39 completed, 6 recruiting, 5 withdrawn, 4 terminated. 62 Phase 2, 22 Phase 1, 1 Phase 3.
Follow Nut and Peanut Hypersensitivity: new trials by email Literature Review of Nut and Peanut Hypersensitivity trials Research Report on Nut and Peanut Hypersensitivity
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| UNC Cashew Sublingual Immunotherapy Cashew sublingual immunotherapy, Placebo sublingual immunotherapy - Cashew Nut Allergy, Tree Nut Allergies | Phase 2 | Not yet recruiting | University of North Carolina, Chapel Hill | 45 | 2027-03-01 | 2026-10-20 |
| Efficacy, Safety and Pharmacokinetics of LP-003 in Peanut Allergic Patients LP-003 Injection, Placebo Injection - Peanut Allergies | Phase 2 | Not yet recruiting | Longbio Pharma (Suzhou) Co., Ltd. | 80 | 2026-12-01 | 2026-11-12 |
| Comparing Standard and Autoclaved Peanut Oral Immunotherapy in People With Peanut Allergy Autoclaved peanut oral immunotherapy, Blanched peanut oral immunotherapy - Peanut Allergy | Phase 2 | Not yet recruiting | McGill University Health Centre/Research Institute of the McGill University Health Centre | 57 | 2026-08-01 | 2026-03-03 |
| Efficacy of Tezepelumab in Peanut Oral Immunotherapy Tezepelumab, Peanut Oral Immunotherapy (OIT), Placebo for Tezepelumab - Peanut Allergy | Phase 2 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 62 | 2026-07-27 | 2026-10-22 |
| UKK-0018 as an Immunotherapeutic for Treatment of Peanut Allergies UKK-0018 - Peanut-Induced Anaphylaxis, Peanut Allergy | Phase 1 / Phase 2 | Recruiting | Ukko Inc | 40 | 2026-02-18 | 2026-10-16 |
| Study of ENP-501 in Peanut-Allergic and Non-Allergic Participants ENP-501, Placebo - Peanut Allergy | Phase 1 / Phase 2 | Recruiting | N-Fold, LLC | 68 | 2025-12-16 | 2026-04-24 |
| Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy RPT904, Placebo - Immune System Diseases, Ig-E Mediated Food Allergy | Phase 2 | Active not recruiting | RAPT Therapeutics, Inc., a member of the GSK plc group of companies | 110 | 2025-12-15 | 2026-11-06 |
| Analysing HIgh Dose Probiotic Peanut Oral Immunotherapy (PPOIT) and High Dose Peanut Oral Immunotherapy (OIT) Versus LOw Dose Peanut OIT for Peanut Allergy Peanut Oral Powder [PEANUT POWDER], Probiotic (LGG®, Lactobacillus Rhamnosus) or placebo probiotic (maltodextrin) - Peanut Allergy | Phase 2 | Withdrawn | Murdoch Childrens Research Institute | 2024-05-01 | 2024-09-19 | |
| Evaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients Microbial Transplantation Therapy, Antibiotic, Placebo (in place of MTT) - Allergy, Peanut, Peanut Allergy | Phase 2 | Recruiting | Rima Rachid | 37 | 2023-06-08 | 2025-08-24 |
| A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy PVX-108, Placebo - Peanut Allergy, Peanut Hypersensitivity | Phase 2 | Active not recruiting | Aravax Pty Ltd | 95 | 2023-02-09 | 2026-11-02 |
| Study of Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With an Allergy to Peanuts LOU064, placebo - Allergy, Peanut | Phase 2 | Completed | Novartis Pharmaceuticals | 76 | 2022-10-12 | 2026-06-12 |
| Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy Peanut SLIT-tablet, Placebo - Peanut Allergy | Phase 1 / Phase 2 | Completed | ALK-Abelló A/S | 209 | 2022-09-07 | 2026-05-11 |
| Open-label Extension Study of ADP101 ADP101 - Food Allergy | Phase 1 / Phase 2 | Terminated | Alladapt Immunotherapeutics, Inc. | 45 | 2022-03-14 | 2024-03-26 |
| Adjuvant Treatment With Abatacept to Promote Remission During Peanut Oral Immunotherapy Abatacept, Placebo, Peanut oral immunotherapy - Peanut Allergy | Phase 2 | Completed | Philippe Bégin | 14 | 2022-03-01 | 2024-11-27 |
| Preventing Anaphylaxis With Acalabrutinib Acalabrutinib - Food Allergy, Food Allergy Peanut | Phase 2 | Completed | Johns Hopkins University | 10 | 2021-12-16 | 2023-09-28 |
| Pinpoint Trial: Prebiotics IN Peanut Oral ImmunoTherapy Prebiotic, Placebo - Peanut Allergy | Phase 1 / Phase 2 | Completed | University of Chicago | 20 | 2021-11-30 | 2026-03-09 |
| STEP-IT-UP - Peanut Allergy Study for Infants Peanut powder or peanut butter - Peanut Allergy, Food Allergy | Phase 2 | Withdrawn | Johns Hopkins University | 2021-11-01 | 2021-11-17 | |
| ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults Low dose ADP101, High dose ADP101, Pooled Placebo - Food Allergy | Phase 1 / Phase 2 | Completed | Alladapt Immunotherapeutics, Inc. | 73 | 2021-04-20 | 2024-05-16 |
| Novel Treatment for Patients With Peanut Allergy: Intralymphatic Immunotherapy Peanut allergen - Food Allergy Peanut | Phase 1 / Phase 2 | Withdrawn | Scripps Health | 2021-03-01 | 2022-11-22 | |
| Oral Immunotherapy for Peanut Allergic Patients INP20, Placebo - Peanut Allergy | Phase 1 / Phase 2 | Recruiting | InnoUp Farma S.L. | 50 | 2020-03-11 | 2025-04-30 |
Showing 20 of 62. Sign in to see all of them.
Peanut Hypersensitivity (59) · Food Hypersensitivity (29) · Hypersensitivity (15) · Hypersensitivity, Immediate (7) · Nut Hypersensitivity (6) · Anaphylaxis (4) · Egg Hypersensitivity (4) · Immune System Diseases (4) · Milk Hypersensitivity (3) · Shellfish Hypersensitivity (2) · Wheat Hypersensitivity (2) · Eczema (1)
Immune System Diseases (58) · Hypersensitivity, Immediate (55) · Hypersensitivity (47) · Food Hypersensitivity (33) · Dermatitis (1) · Skin Diseases (1) · Skin Diseases, Eczematous (1) · Skin and Connective Tissue Diseases (1)
Omalizumab (7) · dupilumab (3) · Abatacept (1) · Anti-Bacterial Agents (1) · Capsules (1) · Glycerol (1) · Histamine Antagonists (1) · Immunotherapy (1) · Ketotifen (1) · Prebiotics (1) · Probiotics (1) · Ranitidine (1) · Vancomycin (1) · acalabrutinib (1) · desloratadine (1)
University of North Carolina, Chapel Hill (12) · Johns Hopkins University (5) · National Institute of Allergy and Infectious Diseases (NIAID) (5) · Aimmune Therapeutics, Inc. (2) · Alladapt Immunotherapeutics, Inc. (2) · DBV Technologies (2) · Massachusetts General Hospital (2) · Novartis Pharmaceuticals (2) · Regeneron Pharmaceuticals (2) · Stanford University (2) · ALK-Abelló A/S (1) · AnaptysBio, Inc. (1) · Aravax Pty Ltd (1) · Assistance Publique - Hôpitaux de Paris (1) · Boston Children's Hospital (1)
United States (45) · Canada (10) · Australia (4) · France (4) · Netherlands (2) · United Kingdom (2) · China (1) · New Zealand (1) · Poland (1) · Spain (1) · Sweden (1) · Switzerland (1)
Wesley Burks, MD (10) · Edwin Kim, MD (4) · Robert Wood, MD (3) · Arvil W Burks, MD (2) · Mei-Lun Wang, MD (2) · Stacie M. Jones, MD (2) · Wayne G Shreffler, MD, PhD (2) · Ana Tabar, PhD, MD (1) · Andrew MacGinnitie, MD, PhD (1) · Andrew T Clark, MB BS MD (1) · Brian Vickery, MD (1) · Bruce Randazzo, MD (1) · Caroline Nilsson, MD, PhD (1)
PMID 38814736, PMID 30978404, PMID 34389504, PMID 41615410, PMID 21281959, PMID 22236732, PMID 23174658, PMID 23265698, PMID 25528358, PMID 25656999, PMID 25705822, PMID 25705823, PMID 25925398, PMID 27297994, PMID 27522159, PMID 27883239, PMID 28091362, PMID 29136445, PMID 29408715, PMID 29700872, PMID 29709643, PMID 31319102, PMID 31329313, PMID 31522849, PMID 31723064, PMID 32434067, PMID 32783912, PMID 33290772, PMID 33463542, PMID 34669990, PMID 34755130, PMID 34813505, PMID 36521802, PMID 37384412, PMID 39673367, PMID 39673452, PMID 39928078, PMID 41488220, PMID 42685867
R01AT004435 (3), 2018 (2), R01AI068074 (1), U19AI066738 (1), U19AI070345 (1), U19AI095261 (1), U19AI104209 (1), U19AI136053 (1)